Status: Recruiting
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Participants needed: 120
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Zhejiang UniversityUpdated: Oct 28, 2020Locations: 1
Eligibility criteria
Histologically confirmed diagnosis of CD19+ ALL, CD19+ NHL, or BCMA+ MM per the... [+13]
History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascul... [+10]